Wegovy in Australia: quick facts
- Active ingredient: semaglutide (weekly GLP-1 receptor agonist) at weight‑management doses up to 2.4 mg.
- TGA status: approved for chronic weight management; pharmacy supply can be constrained and varies by location and dose.
- PBS: not listed for weight loss; private prescription only.
- Access: requires a prescription from an Australian-registered doctor; community or hospital pharmacy dispensing.
- Alternatives: Ozempic (semaglutide), Mounjaro (tirzepatide), Saxenda (liraglutide), Rybelsus (oral semaglutide).
What is Wegovy?
Wegovy is a prescription-only brand of semaglutide formulated for chronic weight management. It is part of the GLP‑1 receptor agonist class and is administered as a once‑weekly subcutaneous injection with a step‑up titration to a typical maintenance dose of 2.4 mg, if tolerated.
In clinical trials combining medication with lifestyle support, high‑dose semaglutide produced average weight loss in the range of around 10–15% at 68 weeks versus placebo. Individual results vary, and safe, sustainable use requires medical supervision.
Compare frameworks and alternatives: Ozempic vs Wegovy, Wegovy vs Saxenda, Mounjaro vs Wegovy.
Who might be eligible in Australia
- Adults with BMI ≥30 kg/m², or
- Adults with BMI ≥27 kg/m² with at least one weight‑related condition (such as hypertension, dyslipidaemia, obstructive sleep apnoea, or cardiovascular risk factors).
Doctors assess suitability based on your medical history, medications, prior attempts at weight management, risk profile and preferences. Some conditions warrant caution or avoidance (see warnings below).
For a deeper dive on prescriber pathways and practical steps, see Wegovy Prescription Australia.
How Wegovy works (GLP‑1 explained)
- Enhances satiety signalling to help reduce hunger and cravings.
- Slows gastric emptying, contributing to smaller portion sizes.
- Improves glycaemic control, which may help reduce swings in appetite.
These mechanisms support, but do not replace, nutrition, sleep, movement and behaviour changes. Most trials paired medication with lifestyle support for best outcomes. Learn more in the broader GLP‑1 Australia Guide and our Weight Loss Injections Australia overview.
Dosing and titration schedule
Typical Australian titration (doctor may adjust based on tolerability):
- Weeks 1–4: 0.25 mg weekly
- Weeks 5–8: 0.5 mg weekly
- Weeks 9–12: 1.0 mg weekly
- Weeks 13–16: 1.7 mg weekly
- Week 17 onward: 2.4 mg weekly (maintenance), if tolerated
If side effects occur, prescribers may extend a step, pause dose increases or consider a lower maintenance dose. Never change your dose without medical advice. See our Wegovy Side Effects guide for mitigation tips discussed in clinics.
Common side effects and key warnings
Common: nausea, vomiting, diarrhoea or constipation, abdominal discomfort or reflux, reduced appetite, fatigue, headache and dizziness. These often occur during dose increases and may settle as your body adapts.
Serious risks (seek urgent care if suspected): signs of pancreatitis (severe persistent abdominal pain), gallbladder problems (upper‑right abdominal pain, fever, jaundice), severe dehydration from vomiting/diarrhoea, allergic reactions, vision changes in people with diabetes, or thoughts of self‑harm.
Do not use Wegovy if you have a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2). Use caution or specialist input if you have a history of pancreatitis, gallstones, severe gastrointestinal disease, diabetic retinopathy or are pregnant, planning pregnancy or breastfeeding.
Full details: Wegovy Side Effects: common reactions, serious risks and when to seek help.
How to access Wegovy in Australia
- Consult an Australian‑registered GP or specialist in‑person or via telehealth to assess suitability and discuss options such as Ozempic, Mounjaro, Saxenda or Rybelsus.
- If appropriate, your doctor may provide a prescription specifically for Wegovy.
- Present the script at a community pharmacy. Availability can vary by dose and region; pharmacies may place you on a waitlist.
- Plan ahead for dose escalations to ensure stock continuity where possible.
Be cautious of non‑pharmacy “research” or imported products marketed as semaglutide or Wegovy. These routes carry legal and safety risks. See: Buy Semaglutide Australia: Legal Access, Red Flags and Safer Routes.
Current availability and supply notes
Australian supply for GLP‑1 medicines has been variable. Some doses or pen strengths may be harder to source at times, and pharmacies may prioritise based on clinical need and supply guidance. If supply is constrained, doctors may discuss alternatives, bridging approaches or deferring dose escalations.
Cost and PBS status
- PBS: Wegovy is not PBS‑listed for weight management; expect private out‑of‑pocket costs.
- Pharmacy pricing: varies by brand, dose and stock. Maintenance dosing generally costs more per month than starter doses.
- Clinic fees: allow for consults, follow‑ups and any care program costs.
For up‑to‑date ranges and budgeting help, see Wegovy Cost Australia.
Wegovy vs other options
- Ozempic (semaglutide): same molecule; indicated for type 2 diabetes; lower labelled doses. Often compared off‑label for weight management. See Ozempic Australia and Ozempic vs Wegovy.
- Mounjaro (tirzepatide): dual GIP/GLP‑1 agonist with strong weight results in trials. See Mounjaro Australia and Mounjaro vs Wegovy.
- Saxenda (liraglutide): daily GLP‑1 injection; older option with different dosing and cost. See Saxenda Australia and Wegovy vs Saxenda.
- Rybelsus (oral semaglutide): tablet form of semaglutide; different dosing and absorption considerations. See Rybelsus Australia.
Frequently asked questions
Is Wegovy available in Australia?
Yes, Wegovy is TGA‑approved for chronic weight management. Pharmacy supply can be limited and varies by state and dose. It is prescription‑only and not PBS‑listed for weight loss.
Who is a typical candidate?
Adults with BMI ≥30 kg/m², or ≥27 kg/m² with weight‑related comorbidities. A doctor will confirm suitability given your history, medications and goals.
How much weight do people lose on average?
In trials combining medication with lifestyle support, high‑dose semaglutide averaged around 10–15% body‑weight reduction at 68 weeks versus placebo. Individual results vary widely.
How does Wegovy differ from Ozempic?
Both contain semaglutide. Wegovy is labelled for weight management at higher maintenance doses; Ozempic is indicated for type 2 diabetes at lower labelled doses. See Ozempic vs Wegovy.
What if I cannot tolerate dose increases?
Doctors often slow titration, extend steps or settle at a lower maintenance dose. Do not change your dose without medical guidance.
Is compounding semaglutide an option?
Compounded products sit under tight and evolving TGA rules. Safety, quality and legal concerns mean most patients should rely on approved brands via pharmacies. Discuss with your prescriber and pharmacist.
Can I import Wegovy for personal use?
Prescription medicines attract strict import and customs rules. Unapproved sources risk seizure and safety issues. Obtain Wegovy through an Australian prescription and pharmacy whenever possible.
What should I read next?
Explore Wegovy Prescription Australia, Wegovy Cost Australia, and Wegovy Side Effects. To compare options, see Mounjaro vs Wegovy and Ozempic vs Wegovy.
Get help with Wegovy access, costs and alternatives
Use this form to request guidance on eligibility, local availability, cost ranges and how Wegovy compares with Ozempic, Mounjaro and Saxenda. We’ll connect you with information and next steps.
For more background, see our pillars: GLP‑1 Australia Guide and Weight Loss Injections Australia.
Key takeaway
Wegovy offers a TGA‑approved, high‑dose semaglutide pathway for weight management in Australia, but access, tolerability and total cost vary. Compare it with Ozempic, Mounjaro, Saxenda and Rybelsus, confirm eligibility with a doctor, and plan around dosing, side effects and pharmacy supply.